Molecular Formula | C26H20F3N7O
|
Molar Mass | 503.48 |
Density | 1.41 |
Solubility | DMSO: 24.7 mg/mL (40 mM)( < 1 mg/ml refers to the product slightly soluble or insoluble) |
Appearance | powder |
Color | white to beige |
pKa | 13.20±0.70(Predicted) |
Storage Condition | -20°C |
MDL | MFCD20272929 |
Use | NVP-BHG712 |
Target | c-Abl; C-Raf; c-Src; EphB4; Tie-2 |
In vitro study | NVP-BHG712 in stably transfected A375 melanoma cells, RTK autophosphorylation was also inhibited in a dose-dependent manner, with EC50 of 25 nM and 4.2 μm for EphB4 and VEGFR2, respectively. |
In vivo study | NVP-BHG712 the model of angiogenesis induced by oral administration of growth factors at a dose of 3 mg/kg significantly inhibits VEGF-stimulated tissue and angiogenesis by inhibiting EphB4 advancing signal. Furthermore, oral treatment of NVP-BHG712 at a dose of 10 mg/kg/kg effectively reversed VEGF-enhanced tissue formation and blood vessel growth. NVP-BHG712 the mice were treated orally at a dose of 3 mg/kg at a concentration of about 10 μm, and the plasma and lung and liver tissues were treated for a long time for up to 8 hours, resulting in long-term inhibition of EphB4 kinase activity. |